NCT00381888View on ClinicalTrials.gov

Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Cervical CancerEndometrial CancerFallopian Tube CancerOvarian CancerSarcomaThromboembolismVaginal CancerVulvar Cancer
Interventions
DRUG

fondaparinux sodium

Fondaparinux, 2.5 mg subcutaneous, Days 1-28 by mouth.

Trial Locations (2)

19013

Crozer-Chester Medical Center, Upland

55455

Masonic Cancer Center at University of Minnesota, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT00381888 - Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer | Biotech Hunter | Biotech Hunter